Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Fully automated assays for colorectal cancer, 2/16

February 2016—Biocartis launched two products on its molecular diagnostics platform Idylla. The first offering, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample. The assay can potentially act as a substitute for tissue biopsy testing in melanoma and colorectal and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. It has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.

H&E tissue staining solution, 2/16

February 2016—Roche launched the Ventana HE 600 system, its latest fully automated hematoxylin and eosin tissue staining system designed to enhance patient and technician safety and produce exceptional staining quality.

BioTheranostics raises $32 million, announces spinout, 2/16

February 2016—BioTheranostics announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, BioTheranostics will be spun out from BioMérieux, which will remain a minority shareholder, and operate as an independent company.

Mouse monoclonal antibodies, 1/16

January 2016—Bio SB introduced Helicobacter Pylori, MMab, Clone: BSB-37, a new line of mouse monoclonal antibodies for IHC with extensive protein immunogenicity analysis of targeted epitopes, high sensitivity specificity, and low background noise.

VEGF ELISA kit, 1/16

January 2016—Enzo Life Sciences launched a VEGF ELISA kit that provides a quantitative, competitive detection method for measuring melatonin in serum, plasma, and cell culture supernants.

Horizon, Swift partnership, 1/16

January 2016—Swift Biosciences will incorporate Horizon Discovery Group’s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.

T2 Bacteria Panel study results, 1/16

January 2016—T2 Biosystems presented data at the AMP annual meeting on its investigational T2Bacteria Panel. The data demonstrate the ability of T2Bacteria to provide rapid and sensitive identification of six sepsis-causing bacteria, directly from whole blood, with limits of detection as low as 1 CFU/mL.

Cystatin C assay, 1/16

January 2016—Beckman Coulter Diagnostics launched its Cystatin C assay for the company’s AU clinical low- to ultra-high-volume family of chemistry systems and Immage 800 immunochemistry systems.

Revised CLSI microbiology document, 1/16

January 2016—The Clinical and Laboratory Standards Institute published a revised document titled “Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria (M45-Ed3).”

Expanded enzyme offering, 1/16

January 2016—Worthington Biochemical announced distribution rights to the Celase GMP compliant enzyme from Cytori Therapeutics. The Celase GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.

MARKETPLACE

TRENDING